Metrics as of 10/16/2026, 11:42 AM (Berlin time), refresh in progress.
Entera Bio Stock
Entera Bio Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- CEO
- Miranda J. Toledano
- Employees
- 21
- Market cap
- $482 M
- IPO
- 28/06/2018
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical…
Entera Bio stock: price history
1D
+10.8%
1W
+10.8%
1M
-3.1%
6M
+130.8%
YTD
+42.8%
1Y
+16.4%
2Y
+58.3%
5Y
-38.7%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~0% stronger price swings than usual
Ask the agents about Entera Bio
Analyst assessment of Entera Bio
PRICE TARGET LOW
US$9.00
CONSENSUS
US$9.00
MEDIAN
US$9.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 27/04/2026
Entera Bio stock metrics
P/E
-7.99
P/B
19.23
EV/EBITDA
-33.02
RETURN ON EQUITY
-100.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.8%
FLOAT SHARES
126,474,913
AVG. DAILY VOLUME (30D)
569,888
Insider transactions (SEC)
Rubin Steven D
Germano Geno J
Ellis Sean
Taitel Haya
Malca Yonatan
Institutional holders
Comparable stocks
Frequently asked questions about Entera Bio stock
What does Entera Bio do?
Entera Bio Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Israel.
The CEO is Miranda J. Toledano, the company employs around 21 people.
The IPO was on 28/06/2018; the stock trades on NASDAQ under the ticker ENTX.
What do analysts say about Entera Bio stock?
4 analysts rate the stock, the consensus is Buy (as of 27/04/2026).
The average price target is US$9.00, ranging from US$9.00 to US$9.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
When does Entera Bio report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does Entera Bio pay a dividend?
No, Entera Bio currently does not pay a dividend.
Which stocks are comparable to Entera Bio?
Comparable stocks include Alpha Tau Medical, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Entera Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Entera Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.